Skip to search formSkip to main contentSkip to account menu

WAY 163909

Known as: WAY-163909, WAY163909 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Prader–Willi syndrome imprinting centre deletion mice have impaired baseline and 5-HT2CR-mediated response inhibition
Abstract Prader–Willi syndrome (PWS) is a neurodevelopmental disorder caused by deletion or inactivation of paternally expressed… 
2018
2018
Impaired cognitive behavioral flexibility following methamphetamine or high caloric diet consumption: a common 5-HT2C mechanism?
Illicit drugs of abuse, such as methamphetamine, can be conceptualized in economic terms as highly purified and potent consumable… 
2017
2017
Synthesis and Structure-Activity Relationships of Tool Compounds Based on WAY163909, a 5-HT2C Receptor Agonist.
The development of probe molecules that can be used to investigate G protein-coupled receptor (GPCR) pharmacology, trafficking… 
2017
2017
Disruption of the serotonin 5-HT2C receptor interaction with protein phosphatase and tensin homologue regulates the behavioral effects of the selective 5-HT2CR agonist WAY163909
2017
2017
The highly selective 5-Ht2c receptor agonist WAY163909 reduces compulsive behavior and food intake in female rhesus monkeys
2009
2009
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
Introduction5-HT2C agonists, by decreasing mesolimbic dopamine without affecting nigrostriatal dopamine, are predicted to have… 
2006
2006
Indole): a Novel 5-ht 2c Receptor Selective Agonist with Preclinical Antipsychotic-like Activity
Serotonin-2C (5-HT2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)